Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 204.8% from a year ago
Other current liabilities stood at $1.52M at the end of Q1 FY2026, up 204.8% from a year earlier and down 70.4% from the prior quarter. Over 3 fiscal years it compounded at +280.2% a year.
Context
- Other current liabilities amounted to 1.5% of total assets at the end of Q1 FY2026, up 1.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +204.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.91M USD
- Year-over-year change
- +225.1%
- 3-year CAGR
- +280.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.91M | +225.1% |
| FY2024 | 2024-12-31 | 896K | +1891.1% |
| FY2023 | 2023-12-31 | 45K | -15.1% |
| FY2022 | 2022-12-31 | 53K | — |
Other Current Liabilities vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 other current liabilities of $1.52M is the 10th highest of the 11 companies compared; the peer median is $4.67M.
- Its year-over-year change of +204.8% is the 2nd highest of 9, against a peer median of +62.8%.
- Other current liabilities amounts to 1.5% of total assets for AARD, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.92M | +412.4% | +57.5% | 10.9% | |
| Mar 2026 | $10.18M | +67.9% | +6.3% | 6.8% | |
| Mar 2026 | $9.79M | — | -11.1% | 15.2% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $6.3M | +199.7% | — | 4.3% |
| Mar 2026 | $5.41M | +170.2% | +7.7% | 2.4% | |
| Mar 2026 | $3.92M | — | — | 1.2% | |
| Mar 2026 | $3.64M | -4.8% | -3.9% | 2.7% | |
| Mar 2026 | $2.64M | +5.9% | +83.3% | 1.5% | |
| Mar 2026 | $2.37M | +29.6% | +132.4% | 1.0% | |
| Mar 2026 | $1.52M | +204.8% | +280.2% | 1.5% | |
ZURAZura Bio Limited | Mar 2026 | $1.13M | +57.7% | +6.1% | 0.5% |
| Peer median (excluding AARD) | $4.67M | +62.8% | +7.0% | 2.6% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.